Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein

Nicolas Escriou a, d, e, Benoît Callendret a, d, f, Valérie Lorin a, d, f, Chantal Combredet b, c, Philippe Marianneau e, Michèle Février b, c, Frédéric Tangy a, c, *,**, 1

* Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France
** CNRS, UMR 7247, F-75015 Paris, France
† Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris, France
‡ Institut Pasteur, Unité de Biologie des Infections Virales Emergentes, Département de Virologie, F-69007 Lyon, France

A R T I C L E  I N F O

Article history:
Received 21 October 2013
Returned to author for revisions 7 November 2013
Accepted 3 January 2014
Available online 28 January 2014

Keywords:
Coronavirus
Severe acute respiratory syndrome
Spike glycoprotein
Measles vaccine

A B S T R A C T

The recent identification of a novel human coronavirus responsible of a SARS-like illness in the Middle-East a decade after the SARS pandemic, demonstrates that reemergence of a SARS-like coronavirus from an animal reservoir remains a credible threat. Because SARS is contracted by aerosolized contamination of the respiratory tract, a vaccine inducing mucosal long-term protection would be an asset to control new epidemics. To this aim, we generated live attenuated recombinant measles vaccine (MV) candidates expressing either the membrane-anchored SARS-CoV spike (S) protein or its secreted soluble ectodomain (Ssol). In mice susceptible to measles virus, recombinant MV expressing the anchored full-length S induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV. As compared to immunization with adjuvanted recombinant Ssol protein, recombinant MV induced stronger and Th1-biased responses, a hallmark of live attenuated viruses and a highly desirable feature for an antiviral vaccine.

† Present address: Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France.

© 2014 Elsevier Inc. All rights reserved.

Introduction

Severe acute respiratory syndrome (SARS) is a newly emerged, human infectious disease that first appeared in China in late 2002. Between November 2002 and July 2003, the virus spread to 29 different countries on 5 continents and was responsible for 8096 clinical cases, leading to 774 deaths (WHO, 2004). WHO case management guidelines and restricted travel advices allowed to bring SARS under control by July 2003. The etiological agent of SARS was identified as a novel coronavirus, named SARS-associated coronavirus (SARS-CoV) (Drosten et al., 2003; Ksiazek et al., 2003) that is genetically distinct from previously characterized members of the Coronaviridae family (Rota et al., 2003). During the 2002–2003 outbreak, SARS-CoV has been isolated in Chinese civets and raccoon dogs (Guan et al., 2003) from which the virus was likely introduced into the human population (Kan et al., 2005; Song et al., 2005). Other SARS-CoV-like viruses sharing more than 88% nucleotide identities with SARS-CoV have been isolated from Chinese horseshoe bats, which have therefore been proposed to represent a natural reservoir host of SARS-CoV (Li et al., 2005). To date, endemic bat SARS-CoV-like viruses have also been detected in Africa and Europe (for review: Balboni et al., 2012), and reemergence of a SARS-like disease from an animal reservoir remains a credible public health threat. An efficient vaccine would be the most effective way to control a new epidemic.

Similar to other coronaviruses, SARS-CoV is an enveloped, positive-stranded RNA virus whose replication takes place in the cytoplasm of infected cells. Viral particles are composed of four major structural proteins: the nucleoprotein (N), the small envelope protein (E), the membrane protein (M), and the large spike protein (S). The spike protein is a type-I transmembrane glycoprotein of 1255 amino acids. It assembles into homotrimers at the surface of viral particles, and gives the virion its crown-like appearance (Neuman et al., 2006). Each monomer (180 kDa) is composed of a signal sequence (a.a. 1–14), a large ectodomain (a.a. 15–1190) with 23 potential N-glycosylation sites, a transmembrane domain (a.a. 1191–1227), and a short cytoplasmic tail of 28 a.a.
(Ksiazek et al., 2003; Rota et al., 2003). The S protein is responsible for viral entry, binds to the cellular receptor ACE2 (Li et al., 2003) and mediates fusion between the viral and cellular membranes (Petit et al., 2005; Simmons et al., 2005). Structurally, the N-terminal globular head (S1 domain, a.a. 1–680) contains the receptor-binding region (Wong et al., 2004), and the membrane-anchored stalk region (S2 domain, a.a. 727–1255) mediates oligomerization and fusion (Petit et al., 2005). Similarly to other coronaviruses, cleavage of the S protein by proteases into its S1 and S2 subunits is required for activation of the membrane fusion domain following binding to target cell receptors (Matsuyama et al., 2010; Simmons et al., 2005).

Due to its critical involvement in receptor recognition, as well as virus attachment and entry, the S protein is the most promising and studied candidate antigen for SARS-CoV vaccine development. It is the major target for neutralizing antibodies in human patients (He et al., 2005; Nie et al., 2004) and in animal models (Buchholz et al., 2004; Tripp et al., 2005). Passive transfer of IgG from convalescent SARS patients enhanced the recovery of acute phase patients when administered within 15 days after the onset of symptoms (Cheng et al., 2005; Yeh et al., 2005). Administration of S-specific antibodies, including monoclonal antibodies, to naïve animals conferred protection against a subsequent SARS-CoV infection, demonstrating that the antibodies alone can protect against SARS in mice (Bish et al., 2004), hamsters (Roberts et al., 2006), ferrets (ter Meulen et al., 2004) and Rhesus macaques (Miyoshi-Akiyama et al., 2011). Accordingly, several candidate vaccines relying on the induction of spike-specific neutralizing antibodies, including DNA vaccines (Callender et al., 2007; Yang et al., 2004), live viral vectors (Buchholz et al., 2004; Chen et al., 2005; Kapadia et al., 2005), live attenuated vaccines (Lamirande et al., 2008), subunit vaccines (Bish et al., 2005; He et al., 2006; Zhou et al., 2005) and inactivated virus vaccine (Stadler et al., 2005; Zhou et al., 2005), have been reported to induce a protective immune response in various animal models. Only a few of them have been evaluated in phase I clinical trials and, lacking a natural challenge, there is no data on efficacy in humans (Roberts et al., 2008; Roper and Rehm, 2009).

An ideal vaccine against SARS should induce long-lasting protective responses after a single administration, be produced at low cost and scaled up to millions of doses. Live attenuated vaccines are particularly appropriate for mass vaccination as they are inexpensive to manufacture and induce a strong immunity and long-term memory after a single injection. To evaluate such a vaccine approach, we previously developed a vector derived from the live-attenuated Schwarz strain of measles virus (MV) (Combredet et al., 2003). MV vaccine is a live-attenuated negative-stranded RNA virus proven to be one of the safest and most effective human vaccines. Produced on a large scale in many countries and distributed at low cost through the Extended Program on Immunization (EPI), this vaccine induces life-long immunity to measles after one or two injections. We previously showed that MV vector stably expressed different proteins from HIV and flaviviruses and induced strong and long-term transgene-specific neutralizing antibodies and cellular immune responses, even in the presence of preexisting immunity to MV (Brandler et al., 2007, 2013; Despres et al., 2005; Guerbois et al., 2009; Lorin et al., 2004). In the present study, we evaluated the immunogenic potential of recombinant MV-SARS vectors expressing either the full-length or the secreted ectodomain of the spike glycoprotein of SARS-CoV. In a mouse model of MV infection, MV-SARS recombinant viruses induced neutralizing antibodies against SARS-CoV and fully protected immunized animals from intranasal challenge with SARS-CoV. Antibody responses induced by MV-SARS vectors were quantitatively and qualitatively compared to responses induced by a prototype subunit vaccine prepared from alum-adjuvanted recombinant Ssol protein.

Results
Recombinant MV Schw-SARS viruses express the SARS-CoV spike glycoprotein, secrete its soluble ectodomain, and replicate efficiently

We synthesized human codon-optimized genes encoding the full-length, membrane anchored SARS-CoV spike (S) protein and its entire ectodomain (residues 1–1193, hereafter designed as Ssol), which is expressed in mammalian cells as a soluble and secreted polypeptide (Callendret et al., 2007, Callendret et al., unpublished results). Their length respects the “rule of six”, which stipulates that the total number of nucleotides into the MV genome must be a multiple of 6 (Calain and Roux, 1993). MV editing- and polyadenylation-like sequences were mutated (Lamb and Kolakofsky, 2001; Schneider et al., 1997). Both S and Ssol sequences were inserted as an additional transcription unit (ATU) into MV vector (pTM-MV Schw plasmid), which contains an infectious MV cDNA corresponding to the anti-genome of the Schwarz vaccine strain (Combredet et al., 2003) (Fig. 1A). The resulting pTM-MV Schw-S and pTM-MV Schw-Ssol plasmids were transfected into helper 293-T MV cells as previously described (Combredet et al., 2003). The corresponding recombinant measles viruses MV-S and MV-Ssol were successfully rescued as indicated by the formation of syncytia, and then propagated in Vero cell culture. We analyzed the replication of MV-S and MV-Ssol viruses on Vero cells by using the same MOI (0.01) than for standard MV stock production (Fig. 1B). The growth of MV-Ssol was only slightly delayed, compared with that of parental empty Schwarz MV (MV Schwarz). The final yield, routinely obtained at 60 h post-infection, was high and identical to that of parental MV schwarz (109 TCID50/ml). Viral growth and yield of MV-S were more affected than that of MV-Ssol. This may be due to reduced MV budding because of the insertion of full length S at the surface of the infected cells, as already observed for MV expressing membrane-anchored forms of HIV gp160 (Lorin et al., 2004).

We analyzed the expression of SARS-CoV spike antigens by indirect immunofluorescence (IFA) of Vero cells infected by recombinant viruses and by immunoblotting of infected-cell lysates. At 48 h post-infection, IFA performed on permeabilized cells using an anti-S hyperimmune mouse ascitic fluid revealed a strong expression of both full-length S and entire ectodomain Ssol of the spike protein along the compartments of the secretory pathway in measles-induced syncytia (Fig. 1C, upper panels). When infected cells were not permeabilized before labeling, only the cell surface of MV-S induced syncytia was readily stained, indicating that the membrane-anchored S is efficiently transported to the surface (Fig. 1C, lower panels). Western blot analysis of cell lysates and supernatants using rabbit anti-S polyclonal antibodies confirmed the expression of S and Ssol proteins in recombinant MV-infected Vero cells with the expected apparent molecular mass of ~180 kDa (Fig. 1D, left panel). Under reducing SDS-PAGE conditions the full length S protein migrates as a doublet, which was described as two differentially glycosylated forms (Song et al., 2004). The lighter product was suggested to be an ER-resident form of the glycoprotein and the heavier a Golgi-processed form containing complex carbohydrates. Other bands of lower molecular weight were also observed that probably correspond to minor degradation fragments, since they were not present at earlier time points (not shown). Expression levels were similar in lysates of MV-infected Vero-NK cells and SARS-CoV infected VeroE6 cells. As expected, the full-length S protein was only detected in cell lysates. In contrast, Ssol was clearly detected both in lysate and supernatant of MV-Ssol infected Vero cells at 40 h after infection (Fig. 1D, right panel), indicating an efficient secretion. Consistently, the Ssol protein secreted in the cell culture medium was heavier than the Ssol observed within cell lysates, which is in agreement with this glycoprotein being synthesized in an immature form in the ER prior to transfer to the Golgi, from which it is secreted.
MV-S and MV-Ssol induce Th1-type immune response and SARS-CoV neutralizing antibodies in mice

The immunogenicity of the recombinant MVSchwarz-SARS viruses was investigated in genetically modified CD46-IFNAR mice susceptible to MV infection (Mrkic et al., 1998) and compared to the immunogenicity of purified S sol peptide produced in mammalian cells, which constitutes a potential subunit vaccine candidate against SARS (Du et al., 2008). The CD46-IFNAR mice express CD46, the human receptor for vaccine MV strains, and lack the INF-α/β receptor. They
have been used previously as a model to evaluate the immunogenicity of recombinant MV (Brandler et al., 2007; Combredet et al., 2003; Despres et al., 2005; Guerbois et al., 2009; Lorin et al., 2004). Eight to twelve-week-old male CD46-IFNAR mice were immunized with two intraperitoneal (i.p.) injections at 4-week interval of $10^5$ TCID$_{50}$ of MV-S or MV-Ssol recombinant viruses. As controls, a group of mice was injected with empty MV vector ($10^5$ TCID$_{50}$) and another group with 2 $\mu$g of purified Ssol protein adjuvanted with 50 $\mu$g of aluminum hydroxide (alum), usual doses for small rodents. Mice sera were collected three weeks after each injection. SARS-CoV- and measles-specific antibody responses were evaluated for each individual mouse by indirect ELISA against SARS-CoV and MV native antigens, respectively.

Significant titers of anti-SARS IgG were raised in all mice after the first injection of recombinant MV-SARS viruses, whereas preimmune sera (not shown) and sera from control animals that received empty MVSchw remained negative (Fig. 2A). These titers were higher for both MV-S and MV-Ssol injected animals (average titer of $3.1 \pm 0.3$ and $2.7 \pm 0.1$ log 10, respectively) than for animals immunized with Alum-adjuvanted Ssol protein ($2.1 \pm 0.3$ log 10 titer, $p < 10^{-3}$). After the second injection, titers were boosted 10–20 times for animals immunized with MV vectors. Tallying with the results observed after the first injection, MV-S induced the highest IgG titers ($4.4 \pm 0.5$ log 10, $p < 0.1$). MV-Ssol induced similar titers ($3.8 \pm 0.2$ log 10) than alum-adjuvanted Ssol protein ($3.8 \pm 0.3$ log 10). Interestingly, antibodies to MV were raised at similar levels in all mice that received either MVSchw or MV-SARS viruses (Fig. 2B), indicating that expression of the heterologous S protein by the recombinant viruses did not alter their replication in vivo nor modify their measles-specific immunogenicity.

![Fig. 2. Antibody response in IFN-α/β−/− CD46+/− mice immunized with MVSchw-SARS recombinant viruses. Groups of 6 IFN-α/β−/− CD46+/− mice were injected twice intraperitoneally at four-week interval with $10^7$ TCID$_{50}$ of the indicated recombinant MVSchw-SARS measles viruses or with parental MVSchw, as control. Another group of mice was immunized with two intramuscular injections of 2 $\mu$g of purified Ssol polypeptide adjuvanted with 50 $\mu$g of aluminum hydroxide (alum). Sera were collected before immunization (PI) or 3 weeks after each injection (IS1 and IS2, respectively). SARS-CoV-specific (A) or MV-specific (B) IgG antibody titers were determined by indirect ELISA, as described in Materials and methods. (C) SARS-CoV-specific, IgG1 (filled circles) and IgG2a (open circles) isotype titers were determined for each IS2 serum by indirect ELISA. (D) SARS-CoV-specific IgA antibody titers were determined for each IS2 serum by indirect ELISA. Values obtained for each individual mouse are represented with circles, with means for each group of mice shown by horizontal bars. Detection limits of the assays are indicated by dotted lines.](image-url)
Additionally, the quality of the humoral response induced by the various immunogens was studied on sera collected 3 weeks after the second injection by IgG and IgA isotype analysis and neutralization assay. We first determined the specific IgG1 and IgG2a isotype titers to the SARS-CoV antigens by anti-SARS ELISA (Fig. 2C). The immunizations with the alum-adjuvanted Ssol protein almost exclusively induced IgG1, indicating that the induced immune responses are predominantly of Th2-type as we previously observed in BALB/c mice (Callendret et al., unpublished results). Contrariwise, MV-S and MV-Ssol viruses induced significantly higher titers of IgG2a than IgG1 antibodies, particularly for MV-S (average ratio IgG2a over IgG1 of 14.7 and 2.7 respectively), reflecting a predominant Th1-type immune response induced by the live recombinant measles vector. Interestingly, MV-Ssol and MV-S viruses also induced moderate (2.4 ± 0.3 log 10) to high titers (3.2 ± 0.3 log 10) of anti-SARS IgA antibodies respectively (Fig. 2D), whereas sera from animals immunized with alum-adjuvanted Ssol protein remained negative (log 10 titer < 1.7).

We then further examined whether the antibody response had SARS-CoV neutralizing activity, which represents the unique correlate of protective immunity against SARS (Enjuanes et al., 2008; Roberts et al., 2008). Neutralizing titers were determined by using an infectivity reduction assay as the highest serum dilution that suppressed SARS-CoV cytopathic effect in at least 50% of the inoculated wells of cultured FRhK-4 cells (Fig. 3). Immunization with MV-Ssol and alum-adjuvanted Ssol protein induced comparable level of neutralizing antibodies (2.4 ± 0.3 and 2.6 ± 0.3 log 10 titer, respectively), whereas MV-S induced significantly three- to four-fold higher neutralizing titers (3.0 ± 0.4 log 10 titer, p < 0.1).

**Immunization with recombinant MV-SARS protects from intranasal experimental challenge**

To determine whether immunization by recombinant MV-SARS could induce protection from an experimental challenge, mice were inoculated intranasally with 10^5 pfu of SARS-CoV five weeks after the second immunization. Mice inoculated with empty MVSchw were used as controls. To evaluate the level of protection against viral replication, we quantified the SARS-CoV infectious titers in lung homogenates prepared two days after challenge (Fig. 4). Control mice immunized with empty MVSchw were all infected except one, SARS-CoV replicating in their lungs at titers up to 10^6 pfu/lung. This shows that CD46-IFNAR mice are susceptible to intranasal SARS-CoV infection, in agreement with previous observations describing a self-limited bronchiolitis with mild or moderate pneumonitis in 129/Sv mice (Hogan et al., 2004) and no increase in susceptibility, pathogenesis and histological outcomes in IFNAR mice of the same genetic background (Frieman et al., 2010).

On the contrary, all mice immunized with MV-S were fully protected from challenge. The absence of SARS-CoV replication was confirmed by quantitative real-time RT-PCR, which evidenced more than a 1000-fold reduction of SARS-CoV RNA levels in the lungs of MVSchw-immunized mice (log 10 geq/lungs < 3.8, below the detection level) compared to MVSchw-immunized mice (7.6 ± 1.9 log 10 geq/lungs). Mice immunized with MV-Ssol or adjuvanted Ssol were also protected, albeit less efficiently; one mouse in either group had low residual viral titers in the lungs (Fig. 4) and SARS-CoV RNA remained detectable albeit at strongly reduced levels in the lungs of half of the immunized mice (not shown).

Altogether, these experiments demonstrate that recombinant MV-SARS viruses expressing either the full-length or the secreted ectodomain of the spike protein induced neutralizing antibodies to SARS-CoV at titers that were sufficient to protect animals from experimental intranasal infection. Noticeably, the efficiency of protection followed the hierarchy observed for neutralization antibody levels, MV-S conferring complete and better protection
from virus replication in mice lungs than both MV-Ssol and the reference adjuvanted subunit vaccine.

Discussion

The objective of this study was to evaluate the proof-of-concept of a new SARS-CoV vaccine strategy based on a standard measles vaccine engineered to express the SARS-CoV spike protein. This strategy might provide a safe recombinant vaccine to protect from SARS-CoV in the regions that might become affected by SARS-CoV re-emergence.

Due to its critical role in viral entry, the S protein is the most promising candidate antigen for SARS-CoV vaccine development (Enjuanes et al., 2008; Roberts et al., 2008; Roper and Rehm, 2009). We designed human codon-optimized genes encoding the full-length SARS-CoV spike (S) protein and its soluble ectodomain (Ssol). These sequences were inserted into MV vector. Recombinant viruses were produced by reverse genetics and grew at standard titers. They expressed high levels of SARS-CoV full-length spike protein at the cell membrane and led to efficient secretion of the soluble ectodomain. Immunization of mice susceptible to MV with recombinant MV-S and MV-Ssol viruses induced specific antibodies that neutralized SARS-CoV infection in vitro. The induction of measles-specific immunity was not altered by the expression of the transgenes. Immunization primed a SARS-CoV-specific memory response that was vigorously boosted by a second injection. The anchored full-length form of the spike protein induced the highest titers of neutralizing antibodies, as we previously observed with HIV gp160 (Lorin et al., 2004), and also a more robust response than a prototype subunit vaccine prepared from adjuvanted recombinant Ssol protein. As compared to immunization with adjuvanted Ssol protein, both recombinant MV-SARS viruses induced higher titers of IgG2a than IgG1 antibodies, indicating a Th1 biased response, a hallmark of live attenuated viruses and a highly desirable feature for an antiviral vaccine. Remarkably, both recombinant MV-SARS vectors also induced SARS-CoV specific IgA, whereas the subunit reference vaccine did not. This raises an interesting point since several clinical studies already evidenced that parenteral administration of live attenuated measles vaccine to children stimulates secretory IgA responses in nasal washes (Bellanti et al., 2004; Simon et al., 2011). Although we did not assess the ability of recombinant MV-SARS to induce secretory IgA in the lungs and upper respiratory tract of immunized mice, this result is strongly indicative of the potential of MV-SARS to induce SARS-CoV specific secretory IgA responses.

To evaluate the efficacy of recombinant MV-SARS vectors, we relied on challenge with wt human SARS-CoV and evaluation of lung virus titers since, unfortunately, mouse-adapted SARS-CoV is not lethal in 129/Sv mice (Frieman et al., 2010). After two successive immunizations with recombinant MV-S virus, all mice were fully protected from intranasal infectious challenge with SARS-CoV and neither infectious virus nor residual viral RNA could be recovered from the lungs of the challenged animals. Interestingly, despite a lower replication rate in cell culture, MV-S conferred a better protection from SARS-CoV replication in mice lungs than MV-Ssol. This may reflect better immunogenicity of the native anchored-form of S or suggest structural dissimilarities between the monomeric soluble Ssol ectodomain and its corresponding membrane-associated trimeric form. In that respect, the absence, or inefficient presentation, of antibody epitopes on truncated soluble immunogens derived from functional virion-associated glycoproteins has already been evidenced for filovirus attachment proteins (Sullivan et al., 2006) and HIV gp160 (Davenport et al., 2011; Kovacs et al., 2012).

Usually given intramuscularly, measles vaccine protects very efficiently against measles disease, which is contracted by aerosolized contamination of the upper respiratory tract, similarly to SARS. Our data demonstrate that parenteral immunization with MV-SARS vector protected mice lungs from SARS-CoV intranasal infection. A similar approach was previously reported by Liniger et al. (2008) that also demonstrated the induction of neutralizing antibodies in mice to SARS-CoV spike expressed by a MV vector. However, this study did not evaluate the efficacy of vaccine preparation to protect immunized mice from SARS-CoV challenge. Our observation that MV-SARS induced a strong Th1 response appears of particular importance given the recently reported safety concerns by Tseng et al., which described Th2-type lung immunopathology upon challenge of mice vaccinated with inactivated whole virus, SARS VLP or alum-adjuvanted S protein (Tseng et al., 2012). They suggested that most previously described vaccine-induced immunopathology might proceed from the same Th2-type immunopathology with prominent eosinophil infiltration upon SARS-CoV challenge. Such effects will likely not occur with live vaccines since they induce potent Th1-biased responses. In agreement with this hypothesis, it was recently reported that a live attenuated SARS-CoV lacking E protein expression provided long-term protection against lethal challenge in an aged-mice model in the absence of any sign of vaccine-induced immunopathology (Fett et al., 2013).

Live attenuated RNA virus vaccines like those against mumps, measles, polio or rubella viruses induce long-term cell-mediated and humoral immunity after one or two injections. Using MV as a vaccination vector presents a number of advantages: this highly efficient and most safe vaccine is easily produced at large scale, vaccine strains are genetically stable, MV does not recombine or integrate genetic material, vaccine does not persist or diffuse. The Schwarz/Moraten strain from which we derived our vector (Combret et al., 2003) is currently the most attenuated and the most widely used measles vaccine. Measles vector expresses very stably large amounts of heterologous genetic material, likely due to the absence of geometric constraints on the size of helicoidal nucleocapsids in this pleiomorphic virus (Tangy and Naim, 2005). Although the stability of expression of the specific SARS transgene remains to be determined, the remarkable genetic stability of added, expressed ORFs has already been described by us and others for a variety of transgenes inserted into measles vector and other members of the Mononegavirales. The measles vector demonstrated a strong capacity to stimulate both cellular and humoral neutralizing immunity against a number of antigens and provided protection from experimental challenge both in mice and primates (Brandler et al., 2007, 2012; Despres et al., 2005; Lorin et al., 2004; Tangy and Naim, 2005). A measles-HIV vaccine candidate currently under clinical development has been evaluated in phase I clinical trial, demonstrating the GMP preclinical and clinical safety and immunogenicity of this vector (Lorin et al., 2012; Stebbings et al., 2012).

Recombinant MV vaccines might be used to immunize both the pediatric and adult/adolescent populations in case of SARS-CoV outbreaks. The presence of anti-MV immunity in nearly the entire adult human population might restrict the use of recombinant MV to naïve infants, an already worthy goal in any event. However, numerous studies have shown that revaccinating immunized individuals results in a boost of anti-MV antibodies, suggesting that the attenuated live vaccine replicates and expresses its proteins in spite of preexisting immunity (Dilihan et al., 2000; Rager-Zisman et al., 2003; Sepulveda-Amor et al., 2002). Likewise, the presence of maternal anti-MV antibodies has been shown to limit the induction of anti-mes measles antibodies but not the induction of specific T-cell responses in infants given measles vaccine during the first year of life (Gans et al., 2003, 2001). Moreover, we
previously demonstrated that recombinant MV vectors were immunogenic and induced protection in the presence of MV preexisting immunity in animal models (Bandler et al., 2013; Lorin et al., 2004), which opens the possibility of using recombinant MV vector to immunize adolescents and adults, although this point needs to be evaluated in human trials. Measles appears very difficult to eliminate and still causes 160,000 deaths annually worldwide, mostly in poorly developed countries (Centers for Disease and Prevention, 2009). Europe also recently experienced severe measles outbreaks (Cottrell and Roberts, 2011). Improving and maintaining measles vaccination for decades is essential to contain this most contagious disease. In this context, the use of recombinant MV designed to immunize the pediatric or adult populations appears desirable.

In conclusion, we have produced new recombinant MV-SARS viruses able to induce neutralizing antibodies to SARS-CoV and full protection from intranasal challenge, thus making the proof-of-concept of this strategy for SARS vaccine development and more generally for severe respiratory infectious diseases. These characterized SARS vaccine candidates deserve to be evaluated in a much more adapted non-human-primate model, in which the cross-protective potential of the induced immune responses against zoonotic SARS isolates/variants could be addressed. Indeed, several studies have underlined the need to induce broadly neutralizing antibodies able to protect against heterologous viral variants, which may arise during independent emergence events (Bolles et al., 2011; Sheahan et al., 2011). Such viral variants, which may arise during independent emergence events (Bolles et al., 2011; Sheahan et al., 2011), may give rise to unneutralized strains with the potential to eliminate and still cause 160,000 deaths annually worldwide, mostly in poorly developed countries (Centers for Disease and Prevention, 2009). Europe also recently experienced severe measles outbreaks (Cottrell and Roberts, 2011). Improving and maintaining measles vaccination for decades is essential to contain this most contagious disease. In this context, the use of recombinant MV designed to immunize the pediatric or adult populations appears desirable.

Materials and methods

Cell lines, viruses and antigens

FRhK-4 (Fetal Rhesus monkey Kidney) and Vero-NK (African Green Monkey Kidney) cells were grown at 37 °C under 5% CO2 in complete DMEM [Dulbecco’s modified Eagle medium with 4.5 mg/ml L-glucose, 100 U/ml penicillin and 100 μg/ml streptomycin], supplemented with 5% heat-inactivated fetal calf serum (FCS) (DMEM-5). Helper 293-T7-MV cells stably expressing T7 RNA polymerase and N and P genes from Schwarz MV were grown in complete DMEM supplemented with 10% FCS (DMEM-10).

SARS-CoV FFM-1 strain (Drosten et al., 2003) was kindly provided by Dr. H.W. Doerr (Institute of Medical Virology, Frankfurt University Medical School, Germany). Viral stocks were produced and titrated as described previously (Callendret et al., 2007). All work involving infectious SARS-CoV was performed in an enhanced biosafety level 3 containment laboratory with rigorous safety procedures according to WHO guidelines.

Crude cell lysates prepared from SARS-CoV infected VeroE6 cells and inactivated frozen by gamma irradiation, as described (Callendret et al., 2007), were used as SARS native antigens for ELISA. A soluble monomeric spike protein, termed Ssol and corresponding to the entire S ectodomain (residues 1–1193) fused with the FLAG tag was produced and purified by immunoaffinity chromatography (Sigma-Aldrich) from the supernatant of stable mammalian cell lines (Callendret et al., unpublished results).

Construction and rescue of recombinant MVSchw-SARS viruses

A human codon-optimized gene encoding the SARS-CoV spike (S) protein of the #031589 specimen (Callendret et al., 2007) was chemically synthesized by Geneart (Regensburg, Germany) and subcloned into the pCI mammalian expression vector (Promega), yielding plasmid pCI-Ssynth. In addition to codon bias optimization, regions of very high (> 80%) or low (< 30%) GC content were avoided whenever possible. Furthermore, cis-acting sequence motifs such as internal TATA-boxes, chi-sites, ribosomal entry sites, ARE, INS, and CRS sequence elements, as well as repetitive sequences, RNA secondary structures and splice donor and acceptor sites, were avoided. The resulting optimized gene had an increased GC content (61.7% from 38.9%). The sequence of the codon-optimized S gene is available upon request. A codon-optimized gene encoding the soluble and secreted spike ectodomain (Ssol) was obtained by PCR amplification using the pCI-Ssynth plasmid as a template and oligonucleotides 5'-ACTAGTACACC GAGTCACCA TGTGCACTT CCTG-3' containing NheI restriction site (underlined) and 5'-AGTAGCCGGA CTGTAGTAC TAC TGCTGCT TGC-3' containing BspE1 restriction site. The PCR fragment was inserted into pCI-Ssol which contains the wild-type non-optimized gene encoding Ssol (Callendret et al., unpublished data), yielding plasmid pCI-Scube.

Measles recombinant vector was derived from plasmid pTM-MVSchw-ATU2 which carries an infectious cDNA corresponding to the anti-genome of the Schwarz MV vaccine strain and an additional transcription unit containing unique restriction sites for the insertion of foreign sequences downstream of the P gene (Combredet et al., 2003) (Fig. 1A). The full-length (S) and secreted (Ssol) spike sequences were amplified by PCR using the pCI-Ssynth or pCI-Scube plasmids as templates and oligonucleotides 5'-ATAAGGATCC CGGGCTCATT ATTTATCGTC GTCATCTTTA TAATC-3 and 5'-ATAGGATCC CGGGCTCATT ATTTATCGTC GTCATCTTTA TAATC-3 containing BsiWI restriction site (underlined) and 5'-ATAAGGATCC CGGGCTCATT ATTTATCGTC GTCATCTTTA TAATC-3 containing BssHI restriction site (underlined). After digestion with BsiWI and BssHI restriction enzymes, the resulting DNA fragments were inserted into the corresponding sites of pTM-MVSchw-eGFP. The sequences inserted into the MV vector respect the “rule of six”, which stipulates that the number of nucleotides of the MV genome must be a multiple of 6 (Calain and Roux, 1993; Schneider et al., 1997). The resulting plasmids pTM-MVSchw-S and pTM-MVSchw-Ssol were used to rescue recombinant viruses using a helper-cell-based system as previously described (Combredet et al., 2003). Single viral clones were amplified on Vero-NK cells. All viral stocks were stored at −80 °C and titrated by an endpoint limiting dilution assay on Vero-NK cell monolayers. Growth curves of recombinant and parental viruses were determined on Vero-NK cells infected at an M.O.I. of 0.01, as described (Combredet et al., 2003).

Analysis of spike protein expression in infected cells

For indirect immunofluorescence assays, monolayers of Vero-NK cells plated on 20 mm glass coverslips in a 12-well plate were infected with the recombinant MVSchw-SARS or parental MVSchw viruses at a multiplicity of infection (M.O.I.) of 0.05. When syncytia were clearly visible but not yet confluent (24–48 h after infection) cells were washed in PBS, fixed with PBS–4% paraformaldehyde for 15 min and in some instances permeabilized with PBS–0.2% Triton X–100 for 10 min. Coverslips were then
incubated for 60 min with anti-S100 hyperimmune mouse ascitic fluid diluted 1/1000 in PBS-1% donkey serum (DKS). After subsequent incubation with a Cy3-conjugated anti-mouse IgG secondary antibody (Jackson Immunoresearch), the samples were mounted on slides with DAPI-containing Vectashield (Vector laboratory) and analyzed under an Axioplan 2 epifluorescence microscope (Zeiss). Pictures were acquired with an Axiocam MRm camera and processed with the Axiovision software (v 4.2, Zeiss).

For western blot assays, cytosolic cell extracts were prepared from Vero-NK cells infected with the recombinant MVSchw-SARS or parental MV-Schw viruses, essentially as described previously (Lorin et al., 2004). Proteins were separated by 8% SDS-polyacrylamide gels and transferred onto a PVDF membrane prior to immunoblotting with rabbit anti-S antibodies, as described (Callendret et al., 2007).

**Mice experiments and characterization of humoral immune responses**

All experiments were approved and conducted in accordance to the Pasteur Institute guidelines in compliance with European animal welfare regulations. To obtain CD46-CD46 mice, the resulting CD46-IFNAR line acquired a uniform genotype. Groups of 6 mice were injected intraperitoneally (i.p.) with 10⁵ PFU of SARS-CoV in 40 μl PBS. Mice were euthanized 48 h after challenge infection. Lung homogenates were prepared in 500 μl DMEM supplemented with 2% FCS and titrated for infectious virus on VeroE6 monolayers, as described (Callendret et al., 2007). Viral RNA was extracted using the QiAamp Viral RNA Mini kit (Qiagen) from 100 μl of tissue homogenates according to the manufacturer’s recommendations, eluted in 60 μl of RNase-free water and analyzed by real-time RT-PCR, as described below. Challenge infection of all animals and subsequent analysis involving infectious materials were done in the “Jean Merieux” biosafety level 4 containment laboratory. Statistical analysis was performed on the log 10 of the viral titers measured for individual mice using the Student’s independent t-test, with the assumptions used for small samples (normal distribution of the variables and same variance for the populations to be compared).

**SARS-CoV genome RNA quantification by real-time RT-PCR**

SARS-CoV genome RNA levels in tissue RNA samples were quantified by real-time RT-PCR with the PRISM 7700 sequence detection system. Briefly, RNA samples (2 μl) were reverse-transcribed and amplified with the TaqMan® One Step PCR Master Mix Reagents Kit (Applied Biosystems) according to the manufacturer’s recommendations, in combination with primer set and fluorogenic probe specific for the nucleoprotein (N) gene (Drosten et al., 2004). Reactions were performed in thermofast® 96-well reaction plates (Abgene) with 25 μl mixtures containing 2 μl of template RNA, 300 nM concentration (each) of primers SAN1 (5’-TGAGCAAC AGATCTAC A3’-3’) and SANPAs2 (5’-GCTTGGAA CAAGCGGCA GTAT-3’) (Eurogentec), and a 100 nM concentration of probe SANP1 (6-FAM-TAACCAGAATGGAGGACGCAATGG-TAMRA) (Eurogentec). The cycling conditions were 45 °C for 15 min, followed by 95 °C for 5 min and then 45 cycles of 95 °C for 15 s and 60 °C for 60 s. Fluorescence was read at the combined annealing-extension step at 60 °C. Absolute quantification of RNA was done by using in vitro transcribed RNA standards prepared from the cloned SARS-CoV N gene and quantified spectrophotometrically. Analytical sensitivity of this real-time N RT-PCR assay was experimentally determined by using limiting serial dilutions of the N RNA standard. Using probit non-linear regression analysis, the 95% detection limit of the RT-PCR was calculated at 40 copies of input RNA per reaction, which corresponded to 3.8 log 10 virus genome-equivalent (geq) per mouse tissue, assuming 100% efficiency in RNA preparation.

**Acknowledgments**

We thank Prof. Dr. H.W. Doerr (Institute of Medical Virology, Frankfurt University Medical School, Germany) for providing us with the SARS-CoV FFM-1 strain. We also thank Dr. Annette Martin for critical reading of the manuscript and helpful suggestions, Prof. Sylvie van der Werf for continuous support and Philippe Loth for expert technical assistance in performing the SARS-CoV challenge experiment. This work was supported in part by Grants from GlaxoSmithKline Biologicals. B.C. was supported by a fellowship from GlaxoSmithKline Biologicals. The funders had no role in

**Challenge infection of animals with SARS-CoV**

Five weeks after the second immunization, animals were lightly anesthetized with isoflurane (Mundipharma) and inoculated intranasally with 10⁵ pfu of SARS-CoV in 40 μl PBS. Mice were euthanized 48 h after challenge infection. Lung homogenates were prepared in 500 μl DMEM supplemented with 2% FCS and titrated for infectious virus on VeroE6 monolayers, as described (Callendret et al., 2007). Viral RNA was extracted using the QiAamp Viral RNA Mini kit (Qiagen) from 100 μl of tissue homogenates according to the manufacturer’s recommendations, eluted in 60 μl of RNase-free water and analyzed by real-time RT-PCR, as described below. Challenge infection of all animals and subsequent analysis involving infectious materials were done in the “Jean Merieux” biosafety level 4 containment laboratory. Statistical analysis was performed on the log 10 of the viral titers measured for individual mice using the Student’s independent t-test, with the assumptions used for small samples (normal distribution of the variables and same variance for the populations to be compared).
Rota, P.A., Oberste, M.S., Monroe, S.S., Nix, W.A., Campagnoli, R., Icenogle, J.P., Roper, R.L., Rehm, K.E., 2009. SARS vaccines: where are we? Expert Rev. Vaccines 8, 1187–1197.

Roberts, A., Lamirande, E.W., Vogel, L., Jackson, J.P., Paddock, C.D., Guarner, J., Zaki, S., Reed, L.J., Muench, H., 1938. A simple method of estimating the protein content of solutions. J. Biol. Chem. 121, 353–360.

Petit, C.M., Melancon, J.M., Chouljenko, V.N., Colgrove, R., Farzan, M., Knipe, D.M., Perlman, S., 2013. The middle East respiratory syndrome (MERS) coronavirus. Curr. Opin. Virol. 3, 432–442.

Neuman, B.W., Adair, B.D., Yoshioka, C., Quispe, J.D., Orca, G., Kuhn, P., Milligan, R.A., Lorin, C., Segal, L., Mols, J., Morelle, D., Bourguignon, P., Rovira, O., Mettens, P., Miyoshi-Akiyama, T., Ishida, I., Fukushi, M., Yamaguchi, K., Matsuoka, Y., Ishihara, T., Schneider, H., Kaelin, K., Billeter, M.A., 1997. Recombinant measles viruses defective in non-structural protein 15 (N protein) are attenuated and protect adult volunteers following intranasal spray delivery of a live attenuated vaccine. Vaccine. 15, 1258–1266.

Li, W., Shi, Z., Yu, M., Ren, W., Smith, C., Epstein, J.H., Wang, H., Crameri, G., Hu, Z., Lai, M.C., Gu, L., Zhou, H.Q., Xiang, H., Zheng, H.J., Chen, L.W., Cheng, C., Fung, P., Pan, C.M., Xuan, H., Chen, S.J., Luo, R.M., Zhou, D.H., Liu, Y.F., He, J.F., Jin, Q., Li, L.H., Ren, Y.Q., Wang, Y., Yu, Y., Anderson, L., Wang, M., Xu, R.H., Wu, X.W., Zheng, H.Y., Chen, J.D., Liang, Q., Gao, Y., Liu, M., Fang, L., Jiang, Y.L., Li, H., Chen, F., Di, B.L., He, J., Lin, Y.J., Tong, S., Kong, X., Du, L., Hao, F., Pang, H., Bernini, A., Yu, X.J., Spiga, O., Guo, Z.M., Pan, H.Y., He, W.Z., Manuguerra, J.C., Fontanet, A., Danich, A., Nicolai, N., Li, Y.X., Wu, C.I., Zhao, G.F., 2005. Cross-host evaluation of severe acute respiratory syndrome coronavirus in palm coatis and human. Proc. Natl. Acad. Sci. USA 102, 2430–2435.

Stadler, K., Roberts, A., Becker, S., Vogel, L., Ickmann, M., Kolesnikova, L., Klenk, H.D., Murphy, B., Rappuoli, R., Abrignani, S., Subbarao, K., 2005. SARS vaccine promotes neutralizing antibody responses in mice. Emerg. Infect. Dis. 11, 1312–1314.

Stebbings, R., Fevrier, M., Li, B., Lorin, C., Koutsoukos, M., Mee, E., Rose, N., Hall, J., Page, M., Almond, N., Voss, G., Yang, T., 2012. Immunogenicity of a recombinant SARS-CoV envelope glycoprotein vaccine in healthy volunteers. Vaccine 30, 7918–7928.

Nie, Y., Wang, G., Shi, X., Zhang, H., Qiu, Y., He, Z., Wang, W., Lian, G., Yin, X., Du, L., Ren, L., Deng, J., He, X., Li, L.T., Deng, H., Ding, M., 2004. Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus. J. Infect. Dis. 199, 1110–1126.

Perlman, S., 2013. The middle East respiratory syndrome – how worried should we be? mBio 4, e00531-13.

Petit, C.M., VLrench, P., and VLrench, R., 2008. Animal models and vaccines for severe acute respiratory syndrome coronavirus (SARS). Curr. Opin. Virol. 8, 157–167.

Song, H.C., SEO, Y.M., Stadler, K., Yoo, B.J., Choi, Q.L., Coates, S.R., Dammatsu, Y., Harada, T., Greer, C.E., Poto, J.M., Pileri, P., Eckmann, M., Rappuoli, R., Abrignani, S., Houghton, M., 2004. Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. J. Virol. 78, 10328–10335.

Song, H.D., Tu, C.C., Zhang, G.W., Wang, S.Y., Zhang, K., Lei, L.C., Chen, Q.X., Gao, Y.W., Zhou, H.Q., Xiang, H., Zheng, H.J., Chen, S.W., Cheng, C., Fung, P., Pan, C.M., Xuan, H., Chen, S.J., Luo, R.M., Zhou, D.H., Liu, Y.F., He, J.F., Jin, Q., Li, L.H., Ren, Y.Q., Wang, Y., Yu, Y., Anderson, L., Wang, M., Xu, R.H., Wu, X.W., Zheng, H.Y., Chen, J.D., Liang, Q., Gao, Y., Liu, M., Fang, L., Jiang, Y.L., Li, H., Chen, F., Di, B.L., He, J., Lin, Y.J., Tong, S., Kong, X., Du, L., Hao, F., Pang, H., Bernini, A., Yu, X.J., Spiga, O., Guo, Z.M., Pan, H.Y., He, W.Z., Manuguerra, J.C., Fontanet, A., Danich, A., Nicolai, N., Li, Y.X., Wu, C.I., Zhao, G.F., 2005. Cross-host evaluation of severe acute respiratory syndrome coronavirus in palm coatis and human. Proc. Natl. Acad. Sci. USA 102, 2430–2435.

Stadler, K., Roberts, A., Becker, S., Vogel, L., Ickmann, M., Kolesnikova, L., Klenk, H.D., Murphy, B., Rappuoli, R., Abrignani, S., Subbarao, K., 2005. SARS vaccine promotes neutralizing antibody responses in mice. Emerg. Infect. Dis. 11, 1312–1314.

Stebbings, R., Fevrier, M., Li, B., Lorin, C., Koutsoukos, M., Mee, E., Rose, N., Hall, J., Page, M., Almond, N., Voss, G., Yang, T., 2012. Immunogenicity of a recombinant SARS-CoV envelope glycoprotein vaccine in healthy volunteers. Vaccine 30, 7918–7928.

Nie, Y., Wang, G., Shi, X., Zhang, H., Qiu, Y., He, Z., Wang, W., Lian, G., Yin, X., Du, L., Ren, L., Deng, J., He, X., Li, L.T., Deng, H., Ding, M., 2004. Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus. J. Infect. Dis. 199, 1110–1126.

Perlman, S., 2013. The middle East respiratory syndrome – how worried should we be? mBio 4, e00531-13.

Petit, C.M., VLrench, P., and VLrench, R., 2008. Animal models and vaccines for severe acute respiratory syndrome coronavirus (SARS). Curr. Opin. Virol. 8, 157–167.

Song, H.C., SEO, Y.M., Stadler, K., Yoo, B.J., Choi, Q.L., Coates, S.R., Dammatsu, Y., Harada, T., Greer, C.E., Poto, J.M., Pileri, P., Eckmann, M., Rappuoli, R., Abrignani, S., Houghton, M., 2004. Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. J. Virol. 78, 10328–10335.

Song, H.D., Tu, C.C., Zhang, G.W., Wang, S.Y., Zhang, K., Lei, L.C., Chen, Q.X., Gao, Y.W., Zhou, H.Q., Xiang, H., Zheng, H.J., Chen, S.W., Cheng, C., Fung, P., Pan, C.M., Xuan, H., Chen, S.J., Luo, R.M., Zhou, D.H., Liu, Y.F., He, J.F., Jin, Q., Li, L.H., Ren, Y.Q., Wang, Y., Yu, Y., Anderson, L., Wang, M., Xu, R.H., Wu, X.W., Zheng, H.Y., Chen, J.D., Liang, Q., Gao, Y., Liu, M., Fang, L., Jiang, Y.L., Li, H., Chen, F., Di, B.L., He, J., Lin, Y.J., Tong, S., Kong, X., Du, L., Hao, F., Pang, H., Bernini, A., Yu, X.J., Spiga, O., Guo, Z.M., Pan, H.Y., He, W.Z., Manuguerra, J.C., Fontanet, A., Danich, A., Nicolai, N., Li, Y.X., Wu, C.I., Zhao, G.F., 2005. Cross-host evaluation of severe acute respiratory syndrome coronavirus in palm coatis and human. Proc. Natl. Acad. Sci. USA 102, 2430–2435.